|
|
|
|
|
|
|
| Compound Library Consortium | White Paper | By Muralikrishna Valluri, Ph.D. & Douglas B. Kitchen, Ph.D., Curia | Explore how a novel approach to enhancing drug discovery efforts can significantly improve the chances of identifying promising drug candidates, ultimately accelerating the path from discovery to development. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Well, that didn’t work out as planned, writes Chief Editor Louis Garguilo, referring to Kodak's strategy in 2018 to revitalize the Eastman Business Park in Rochester, NY. The incoming chairman and now CEO, Jim Continenza, didn’t like that movie, and flipped the script. Instead, Kodak has, so to speak, returned to itself – back to a domestic specialty materials and chemicals supplier, intent on serving biopharma in that capacity. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
| De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept | Article | By Andreas Reichl, M.D., and Kevin Schaab, Ph.D., Quotient Sciences | Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|